Abstract | AIMS: Novel anticancer strategies have employed bacteriophages as drug carriers and display platforms for anticancer agents; however, bacteriophage-based platforms maintain their natural antibacterial activity. This study provides the assessment of combined anticancer (engineered) and antibacterial (natural) phage activity in therapies. MATERIALS & METHODS: RESULTS & CONCLUSION:
Tumor growth was decreased in mice treated with YIGSR-displaying phages. The acuteness of wounds, bacterial load and inflammatory markers in phages-treated mice were markedly decreased. Thus, engineered bacteriophages combine antibacterial and anticancer activity.
|
Authors | Krystyna Dąbrowska, Zuzanna Kaźmierczak, Joanna Majewska, Paulina Miernikiewicz, Agnieszka Piotrowicz, Joanna Wietrzyk, Dorota Lecion, Katarzyna Hodyra, Anna Nasulewicz-Goldeman, Barbara Owczarek, Andrzej Górski |
Journal | Future microbiology
(Future Microbiol)
Vol. 9
Issue 7
Pg. 861-9
( 2014)
ISSN: 1746-0921 [Electronic] England |
PMID | 25156375
(Publication Type: Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Bacterial Agents
- Antineoplastic Agents
- Peptides
|
Topics |
- Animals
- Anti-Bacterial Agents
(administration & dosage, metabolism)
- Antineoplastic Agents
(administration & dosage, metabolism)
- Bacterial Infections
(therapy)
- Bacteriophage T4
(genetics, metabolism)
- Biological Therapy
- Drug Delivery Systems
(methods)
- Escherichia coli
(virology)
- Female
- Gene Expression
- Humans
- Mice
- Mice, Inbred BALB C
- Neoplasms
(drug therapy)
- Peptides
(administration & dosage, genetics, metabolism)
|